Table 1.
Baseline characteristics of patients.
| Median (range) or N (%) | |
|---|---|
| Total number of patients | 68 (100%) |
| Diagnosis type | |
| Localized AL controls | 12 (18%) |
| MGUS | 12 (18%) |
| Smoldering MM | 11 (16%) |
| MM within 6 months from diagnosisa | 15 (22%) |
| Relapsed MMb | 18 (26%) |
| Age at sample collection, years | 65 (43–85) |
| Female sex | 31 (46%) |
| High risk FISHc | 20 (53%) |
| Follow-up from diagnosis, months (controls excluded) | 57 (3–154) |
| BMPC % at sample collection | |
| MGUS | 2.5% (0–7.5%) |
| Smoldering MM | 14% (8–50%) |
| Active MM | 50% (0–90%) |
| Time to hematologic progression from sample collection, months | |
| MM within 6 months from diagnosis | 15 (5–68) |
| Relapsed MM | 5 (1–33) |
| Received osteoclast inhibitors within 6 monthsd (controls excluded) | 20/56 (36%) |
| MGUS | 1/12 (8%) |
| SMM | 2/11 (18%) |
| Active MM | 17/33 (52%) |
| Any skeletal fracture within 6 months from sample collectione | 15 (45%) |
FISH fluorescent in-situ hybridization, MM multiple myeloma.
aOf which 12 were newly diagnosed and 3 patients were after induction therapy (1 partial response and 2 very good partial responses).
bOf which 12 triple-refractory.
cConsidered for smoldering and active MM and only for the 38 patients with complete FISH data. Defined as presence of deletion 17p, t (4;14), +1q, t(14;16) or t(14;20).
dOf which 14 patients received zoledronic acid, 3 alendronate and 3 pamidronate.
eConsidered for the 33 patients with active MM.